Innovative Biomarkers of Cardiovascular Complications Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Treatments: a Single-center Cohort Study

计划入组 100 人 · 首次发布于 2025 年 9 月 15 日

Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib

计划入组 65 人 · 首次发布于 2021 年 10 月 5 日

Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI

计划入组 24 人 · 首次发布于 2026 年 9 月 14 日

Acalabrutinib(Calquence)

C₂₆H₂₃N₇O₂ · Rx

Tyrosine(Premasol, Clinimix E 2.75/5, Aminosyn-PF 7%, Primene, Clinimix 2.75/5, Trophamine 10 %, Plenamine, Olimel, Prosol, Clinisol 15, Periolimel, Travasol 10)

C₉H₁₁NO₃

Bruton's tyrosine kinase inhibitor(TargetRx)

Inhibikase Therapeutics

United States

Cogent Biosciences

United States

Exelixis, Inc.

United States

Ibrutinib Shows Promise in Treating Chronic Graft-Versus-Host Disease

Infection Risk With BTK Inhibitors Low, New CLL Study Finds

Study Finds No Benefit in Pausing BTK Inhibitors During COVID-19 Vaccination for CLL Patients